Medicinova Stock Price, News & Analysis

MediciNova, a biopharmaceutical company (NASDAQ:MNOV), will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, 2021. CEO Yuichi Iwaki and VP Geoffrey O'Brien will hold one-on-one meetings, with investor requests facilitated through Morgan Stanley. MediciNova develops therapies for inflammatory and neurodegenerative diseases, with its lead asset MN-166 in Phase 3 trials for ALS and DCM. The company has a diverse pipeline, with additional clinical programs underway for multiple conditions.

MediciNova, Inc. (NASDAQ: MNOV) announced that an abstract titled Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD will be presented at The Liver Meeting® 2021, occurring from November 12-15, 2021. Dr. Masatsune Ogura from Chiba University will present findings on MN-001's (tipelukast) effects on lipid metabolism, notably its ability to suppress triglyceride synthesis and lower serum triglyceride levels. MN-001 aims to treat NASH/NAFLD through novel anti-inflammatory and anti-fibrotic mechanisms, with additional potential applications in various fibrotic diseases.

MediciNova, a biopharmaceutical company (NASDAQ:MNOV), announced the acceptance of an abstract regarding its Phase 2b/3 trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND, set for December 7-10, 2021. The presentation will be led by Chief Medical Officer Kazuko Matsuda. The COMBAT-ALS trial aims to assess efficacy and safety with 230 participants across the U.S., Canada, and Europe. MN-166 is also in development for other neurodegenerative diseases and conditions like glioblastoma and ARDS.

MediciNova, Inc. (NASDAQ: MNOV) reported significant advancements in its drug development pipeline in its Q2 2021 update. The company initiated preclinical studies for MN-166 (ibudilast) targeting chlorine gas-induced lung disease, with positive Phase 2 results in alcohol use disorder published in Nature Journal, reinforcing MN-166's safety and potential. Ongoing patient enrollment continues for the Phase 3 trial of MN-166 in amyotrophic lateral sclerosis (ALS). Financially, MediciNova reported a cash balance of $77.8 million, projected to support operations through 2022.

MediciNova, trading on NASDAQ under the symbol MNOV, announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering MN-166 (ibudilast) for treating ophthalmic diseases. This patent could extend protection until at least October 2039 and includes claims for treating macular injury. The drug is also in late-stage clinical trials for various neurodegenerative diseases, with encouraging results from previous studies. The patent may enhance MN-166's commercialization potential.

MediciNova, a biopharmaceutical company, announced that its leadership will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, at 4:30 pm ET. They will discuss their innovative clinical pipeline, including MN-166 (ibudilast), currently in Phase 3 trials for ALS and DCM. Additionally, MN-001 (tipelukast) is in Phase 2 trials for idiopathic pulmonary fibrosis. Investors can request one-on-one meetings via Ladenburg Thalmann.

MediciNova (NASDAQ: MNOV) has announced a mouse study to assess the efficacy of MN-166 (ibudilast) in treating chlorine-induced lung injuries. Conducted in partnership with BARDA, this study will evaluate survival rates and clinical outcomes following exposure to chlorine gas. MN-166 has shown potential in alleviating pulmonary damage and reducing inflammation in previous studies. MediciNova is leveraging federal funding for this project, which aligns with its broader development efforts for MN-166 in treating neurodegenerative diseases and acute respiratory conditions.

MediciNova, Inc. announced positive results from a Phase 2 trial of MN-166 (ibudilast) for treating alcohol use disorder (AUD) published in Nature’s Translational Psychiatry. The trial demonstrated a 45% reduction in heavy drinking odds and reduced alcohol craving on non-drinking days. The study involved 52 participants and aimed to assess mood and neural activation related to alcohol cues. These findings indicate potential for MN-166 as a novel AUD treatment, addressing the unmet medical need for effective therapies.

MediciNova, a biopharmaceutical company trading as MNOV, announced a fireside chat with CEO Yuichi Iwaki and VP Geoffrey O'Brien on June 23, 2021, at 1:00 pm ET, hosted by Maxim Group's Jason McCarthy. The company is focused on developing therapies for neurodegenerative, inflammatory, and fibrotic diseases, with MN-166 in Phase 3 trials for ALS and DCM. The drug is also in Phase 2 trials for glioblastoma and ARDS. MN-001 is in Phase 2 for idiopathic pulmonary fibrosis. MediciNova has 11 active clinical programs and is known for securing grants for its trials.